Bioventus (BVS)
(Delayed Data from NSDQ)
$11.79 USD
-0.16 (-1.34%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $11.78 -0.01 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
BVS 11.79 -0.16(-1.34%)
Will BVS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BVS
Beat the Market Like Zacks: Talen Energy, CBRE, 3M in Focus
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen
Other News for BVS
Bioventus announces divestiture of its Advanced Rehabilitation business to Accelmed Partners
Bioventus divesting advanced rehabilitation business to Accelmed Partners
Bioventus Inc (BVS) Trading 10.09% Higher on Sep 27
Bioventus price target raised by $5 at Craig-Hallum, here's why
Bravura Solutions Continues Share Buy-Back